FirstWord

Patients on Akeso and Summit's PD-1/VEGF bispecific lived a median 2.8 months longer in a Chinese Phase III study.

Detailed Phase III data show a 53% reduction in the risk of death with sonesitatug vedotin in heavily pretreated patients, despite a miss on progression-free survival.

The combination regimen achieved a progression-free survival of 7.6 months, a statistically significant result compared with 5.4 months for chemotherapy.

Company says the Phase III DASL-HiCaP study supports adding the drug to radiation and hormone therapy for patients at high risk of recurrence.

Phase III results from the VOLGA trial show significant survival gains with the two-drug regimen, though the rival Padcev-Keytruda combo sets a high competitive bar.

Genmab's latest antibody-drug conjugate (ADC) data takes direct aim at AbbVie and Elahere with potentially practice-changing results in ovarian cancer, while validating its buyout of Profoundbio.

FirstWord hosted an expert call with Vanderbilt's Douglas Johnson to discuss the implications of Merck & Co. and Moderna's Phase III INTer-path001 study for melanoma and what potential readthrough the results have for neoantigen therapies in other indications.

Use of Imdelltra plus AstraZeneca's Imfinzi in the first-line maintenance setting not only demonstrated unprecedented survival benefits, but significantly enhances the safety profile of Amgen's therapy relative to use in second-line patients.

Moderna and Merck & Co.'s cancer vaccine has set a new benchmark in adjuvant melanoma, but there are few clues whether it will work in other tumours.

25-Oct-2026 at 10:15 AM EDT, by The University of Texas MD Anderson Cancer Center contact patient services ABSTRACTS: 3438O, 4244RO, 540RO, 2490PMADRID, OCTOBER 26, 2026 ― Researchers at The Universit...